Search This Blog

Wednesday, June 17, 2026

Rigel closes exclusive global license deal with Arvinas and Pfizer for VEPPANU

 

Rigel closes exclusive global license deal with Arvinas and Pfizer for VEPPANU, receives $70M upfront, targets August launch

  • Agreement for breast cancer drug VEPPANU (vepdegestrant) became effective June 11, 2026.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)